Provides a state-of-the-art overview of the evidence on the critical role of bradykinin B2 receptor in the pathogenesis of bradykinin-mediated angioedema Explains the scientific foundation for targeting the bradykinin B2 receptor as a therapeutic strategy for additional bradykinin-mediated diseases

HSC-based humanized mouse model of pulmonary fibrosis achieves stable multilineage human immune engraftment without graft-versus-host disease Nintedanib treatment confirms clinically consistent drug response, validating the model for evaluation of human-specific biologics and cell therapies International patent filed under the Patent Cooperation Treaty in February 2026, with national phase entries

Cytosurge has appointed veteran biotech executive and investor Luba Greenwood, J.D., to its Board of Directors. With deep expertise across biotech, AI, and venture capital, Greenwood joins to accelerate Cytosurge’s US expansion and scale its Same-Cell Biology platform. By generating true causal data from living cells before and after intervention, Cytosurge aims to solve the critical data bottle